Informed Managed Care Decision-Making in the Management of Endometrial Cancer: Optimizing Immunotherapy for Improved Patient Outcomes.
Immunotherapy with checkpoint inhibitors has become a promising treatment option for treating advanced endometrial cancer. While initially used in the second-line or later setting, these therapies are being used in combination with standard of care chemotherapy in the first-line treatment setting. I...
| Publicado en: | Journal of Managed Care Medicine Vol. 28; no. 2; pp. 14 - 20 |
|---|---|
| Autor principal: | |
| Formato: | tables/charts Journal Article |
| Publicado: |
National Association of Managed Care Physicians, Inc.
2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=192606124&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 192606124 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 10941525 9084 jtl: Journal of Managed Care Medicine issn: 10941525 maglogo: N pubinfo: dt: 2025 vid: 28 iid: 2 pid: 54351 pub: National Association of Managed Care Physicians, Inc. place: Glen Allen, Virginia artinfo: ui: 192606124 192606124 192606124 192606124 ppf: 14 ppct: 6 formats: fmt: @attributes: type: P tig: atl: Informed Managed Care Decision-Making in the Management of Endometrial Cancer: Optimizing Immunotherapy for Improved Patient Outcomes. aug: au: Monk, Bradley J. affil: Medical Director of Late-Phase Clinical Research at the Florida Cancer Specialists and Research Institute in West Palm Beach, FL sug: subj: Endometrial Neoplasms Therapy Decision Making, Clinical Quality Improvement Immunotherapy Treatment Outcomes Immune Checkpoint Inhibitors Biological Markers Chemotherapy, Cancer Neoplasm Recurrence, Local Therapy ab: Immunotherapy with checkpoint inhibitors has become a promising treatment option for treating advanced endometrial cancer. While initially used in the second-line or later setting, these therapies are being used in combination with standard of care chemotherapy in the first-line treatment setting. Improvements in progression-free survival and overall survival are being shown with immunotherapy/chemotherapy combinations. pubtype: Academic Journal doctype: tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|